CompletedPhase 2NCT04923594

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Studying Narcolepsy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: NLS Pharmaceutics
Principal Investigator: Carlos Camozzi, MD
NLS Pharmaceutics
Intervention: mazindol extended release(drug)
Enrollment: 67 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2021 – 2022

Study locations (22)

Sleep Disorders Center of Alabama, Birmingham, Alabama, United States
Stanford Sleep Medicine Center, Redwood City, California, United States
Pacific Research Network, San Diego, California, United States
St. Francis Sleep Allergy and Lung Institute, Clearwater, Florida, United States
Sleep Medicine Specialists of South Florida, Miami, Florida, United States
Ivetmar Medical Group, Miami, Florida, United States
The Angel Medical Research Corporation, Miami Lakes, Florida, United States
Treken Primary care, Atlanta, Georgia, United States
NeuroTrials Research, Atlanta, Georgia, United States
Clinical Research Institute, Stockbridge, Georgia, United States
Hawaii Pacific Neuroscience Clinical Research Center, Honolulu, Hawaii, United States
The Center For Sleep & Wake Disorders, Chevy Chase, Maryland, United States
Sleep and Attention Disorders, Sterling Heights, Michigan, United States
Neurology and Sleep Disorders Clinic, Columbia, Missouri, United States
Carolinas Sleep Specialists, Concord, North Carolina, United States
+7 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04923594 on ClinicalTrials.gov

Other trials for Narcolepsy

Additional recruiting or active studies for the same condition.

See all trials for Narcolepsy →

← Back to all trials